Dawn of a New Era for Kinase Drug Discovery: Kinome Wide Profiling and Screening Solutions Coupled to Functional Cell-based Assays Enable Launch of Selective and Functional Kinase Inhibitors
White Paper May 09, 2011
It is no mystery that the global drug discovery market is continuously under pressure to perform against rapidly shifting regulations, timelines and performance data while balancing meaningful innovation and profitability. The industry is rising to the challenge as innovative new drug discovery technologies are fueling continuous improvements across the effectiveness of marketed drugs while minimizing potential adverse side effects. This is where novel product and service portfolios from companies like DiscoveRx® play a pivotal role in offering a range of GPCR and Kinase based tools that give their customers the power to discover new drugs.
Related White Papers
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018